Donald Allen  Williams net worth and biography

Donald Williams Biography and Net Worth

Director of Palisade Bio

Mr. Williams has more than 40 years of experience in the accounting and finance sector, including 36 years in the public accounting industry and over four years serving on the board of various public and private companies. His public accounting experience includes 18 years as a partner with Ernst & Young, and seven years as a partner with Grant Thornton. With a primary industry focus in the life sciences/healthcare and technology sectors, he served companies involved in the extended care market, acute care market, and roll-up transactions involving physicians, dentists and ambulatory surgery centers while at Ernst & Young. During his time at Grant Thornton, he served as national leader of the life sciences industry sector and managing partner of the San Diego Office. From 2001 to 2014, Mr. Williams served on the board of directors of the San Diego Venture Group, during which time he also served as the group’s President and Chairman. He was also a founding member of the Young VCs of Southern California.

Mr. Williams currently serves on the board of directors of Adhera Therapeutics, Akari Therapeutics, Alphatec Spine, and ImpediMed. He received a Bachelor’s degree in Accountancy from Southern Illinois University and completed the director education and certification program at the University of California, Los Angeles (UCLA) Anderson School of Business.

What is Donald Allen Williams' net worth?

The estimated net worth of Donald Allen Williams is at least $1.97 thousand as of May 28th, 2024. Mr. Williams owns 1,000 shares of Palisade Bio stock worth more than $1,970 as of May 5th. This net worth estimate does not reflect any other investments that Mr. Williams may own. Learn More about Donald Allen Williams' net worth.

How do I contact Donald Allen Williams?

The corporate mailing address for Mr. Williams and other Palisade Bio executives is 20271 Goldenrod Lane, Germantown MD, 20876. Palisade Bio can also be reached via phone at (858) 704-4900 and via email at [email protected]. Learn More on Donald Allen Williams' contact information.

Has Donald Allen Williams been buying or selling shares of Palisade Bio?

Donald Allen Williams has not been actively trading shares of Palisade Bio during the past quarter. Most recently, on Tuesday, May 28th, Donald Allen Williams bought 1,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $4.86 per share, with a total value of $4,860.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $4,860. Learn More on Donald Allen Williams' trading history.

Who are Palisade Bio's active insiders?

Palisade Bio's insider roster includes John Finley (CFO), Thomas Hallam (CEO), Robert Trenschel (Director), and Donald Williams (Director). Learn More on Palisade Bio's active insiders.

Are insiders buying or selling shares of Palisade Bio?

During the last year, insiders at the sold shares 2 times. They sold a total of 5,885 shares worth more than $10,298.75. The most recent insider tranaction occured on February, 12th when insider Mitchell Lawrence Jones sold 1,989 shares worth more than $3,480.75. Insiders at Palisade Bio own 0.1% of the company. Learn More about insider trades at Palisade Bio.

Information on this page was last updated on 2/12/2026.

Donald Allen Williams Insider Trading History at Palisade Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/28/2024Buy1,000$4.86$4,860.001,000View SEC Filing Icon  
1/31/2024Buy666$9.00$5,994.002,000View SEC Filing Icon  
9/27/2023Buy1,333$8.10$10,797.301,333View SEC Filing Icon  
See Full Table

Donald Allen Williams Buying and Selling Activity at Palisade Bio

This chart shows Donald Allen Williams's buying and selling at Palisade Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palisade Bio Company Overview

Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More

Today's Range

Now: $1.97
Low: $1.96
High: $2.21

50 Day Range

MA: $1.96
Low: $1.60
High: $2.80

2 Week Range

Now: $1.97
Low: $0.53
High: $2.86

Volume

4,586,350 shs

Average Volume

4,388,145 shs

Market Capitalization

$329.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52